SEC Filing Summary for Beam Therapeutics Inc.

This filing details a transaction by John M. Evans, CEO and Director of Beam Therapeutics Inc. On April 1, 2026, Mr. Evans automatically sold 30,078 shares of common stock at $24.58 per share, totaling $739,158.24. This sale was part of a non-discretionary transaction to cover tax withholding obligations upon the vesting of restricted stock units granted under the company's 2019 Equity Incentive Plan. The sales were executed under a Rule 10b5-1 trading plan. Following this transaction, Mr. Evans directly owns 1,047,205 shares. Additionally, the filing notes the acquisition of 616 shares by Mr. Evans under the company's Employee Stock Purchase Plan on March 31, 2026. Indirectly, 103,000 shares are held by the John M. Evans, III 2018 Irrevocable Trust.